The volunteer said he had also volunteered 10 years ago for clinical trials for a vaccine against the H1N1 (swine flu) virus.
The Corosure Kit has received ICMR approval with the highest score and DCGI approved with a very high sensitivity and specificity.
Addressing a press briefing, Union Health Ministry Secretary Rajesh Bhushan said on the basis of a seven-day rolling average the positivity rate of COVID-19, which was 11 per cent during the first week of August, has come down to 8 per cent now.
Accusing Rahul Gandhi of trying to "weaken" the country's resolve to fight COVID-19, the Bharatiya Janta Party said on Wednesday that the Congress leader has been acting in a "most irresponsible" manner and is trying to mislead the country with "falsehoods and misrepresentation of facts".
AIIMS-Delhi is among the 12 sites selected by the Indian Council for Medical Research (ICMR) for conducting Phase I and II randomised, double-blind and placebo-controlled clinical trials of Covaxin.
The highest number of confirmed cases are from Maharashtra (748), followed by Tamil Nadu at 571 and Delhi with 523 cases. Cases in Telangana have gone up to 321, in Kerala to 314, in Uttar Pradesh to 305, while the number of cases has gone up to 274 in Rajasthan.
In the wake of 73 confirmed cases of coronavirus in India so far, the Union health ministry has made functional 52 laboratories for testing samples while 57 labs have been designated for helping in sample collection for Covid-19 to enhance capacity for diagnosis and detection of the disease. "Following the increase in load of screening samples from suspected cases with symptoms and travel history to the affected countries, the department of health research/ICMR has commissioned 52 laboratories for COVID-19 testing in India," an official said.
The sub-group constituted by the Supreme Court to audit oxygen consumption in hospitals in the national capital during the second wave said the Delhi government "exaggerated" the consumption of oxygen and made a claim of 1,140 MT, four times higher than the formula for bed capacity requirement of 289 MT.
He also ordered discontinuation 'with immediate effect' of the services of a private agency which was making telephonic contact with home-quarantined individuals to guide them.
The rise in fresh Covid cases and the effective reproduction number -- indication of how fast an infection spreads -- in many states is worrying but don't panic. Instead, mask up and get vaccinated, say experts, stressing that it is too early to declare the beginning of a new wave.
India's COVID-19 recovery rate rose to 63.13 per cent on Wednesday with a record 28,472 patients recuperating from the disease in 24 hours, while the case fatality rate further dropped to 2.41 per cent, the Union health ministry said.
India's COVID-19 tally had crossed the 20-lakh mark on August 7.
The number of recoveries has surged to 14,80,884 with 53,879 coronavirus patients having recuperated and discharged in 24-hours, the highest in a day so far.
Alternatively, the government may go in for a five-day session to blunt criticism that it was running away from debates.
The CoWIN portal will be made available in Hindi and 14 regional languages by next week, while 17 more laboratories will be added to the INSACOG network to monitor the variants of COVID-19, the health ministry said on Monday.
A total of 27,920 people have been cured of the disease with 1,685 in the last 24 hours, taking the recovery rate to 34.06 per cent, the ministry said.
There are 907883 active cases of coronavirus infection in the country which comprises 13.44 per cent of the total caseload, the data stated.
Each vaccination session will cater to a maximum of 100 beneficiaries and the Union Health Ministry has advised states not to organise 'unreasonable numbers of vaccination per site per day'.
The ministry of health and family welfare spent Rs 3,948 crore in May this year compared to Rs 7,816 crore in the corresponding month of the previous year. On the other hand, at Rs 12,930 crore, the expenditure had risen almost 200 per cent in April against Rs 4,327 crore in the corresponding month of 2019-20.
Five vaccine candidates are in advanced stages of development in India, out of which four are in Phase II/III and one is in Phase-I/II trials.
The third phase trial of Bharat Biotech's Covaxin began in the state on Friday and the 67-year old senior Bharatiya Janata Party leader was administered the trial dose at the Civil Hospital at Ambala Cantt.
Dr Rai, who is also a principal investigator of the Bharat Biotech Covaxin clinical trial at AIIMS, said that COVID-19 preventive measures like wearing masks, hand hygiene should be followed till there is an effective vaccine.
The districts are Gondia (Maharashtra), Raj Nand Gaon (Chhattisgarh), Davangiri (Karnataka), South Goa, Wayanad and Kottayam (Kerala), West Imphal (Manipur), Rajouri (J&K), Aizwal West (Mizoram), Mahe in Puducherry, SBS Nagar in Punjab, Patna, Nalanda and Munger in Bihar, Pratapgarh in Rajasthan, Panipat, Rohtak and Sirsa in Haryana, Pauri Garhwal in Uttrakhand and Bhadradari Kothagudem in Telangana.
The Pune-based vaccine major has entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.
People aged 45 and above account for about 88 per cent of all COVID-19 deaths in India making them the most vulnerable section, the Union health ministry said on Wednesday, a day after the government opened up vaccinations for all those in the age bracket from April 1.
Sadananda Gowda, the minister, also Bengaluru North MP, drove off in an official car with out undergoing institutional quarantine as mandated by the Karnataka government for air travellers coming from high COVID-19 prevalence states after arriving by a commercial airline flight, services of which resumed after two months.
Of the total cash outgo Rs 40,000 crore is towards enhanced expenditure under Mahatma Gandhi National Rural Employment Guarantee Program and Rs 33,771.48 crore have been sought for direct benefit transfer under Pradhan Mantri Jan Dhan Yojana and National Social Assistance Programme.
The govt said that states have been asked to classify districts which have reported a higher number of cases as hotspots, the districts where cases have been reported as non-hotspots, and green zones where no cases have been reported.
The prime minister is likely to talk about its possible extension.
The death toll climbed to 66,333 with 1,045 more fatalities reported in 24 hours.
The total of 103 deaths reported since Thursday morning include 43 in Maharashtra; 29 in Gujarat; eight in Madhya Pradesh; seven in West Bengal; five in Rajasthan; two each in Tamil Nadu, Uttar Pradesh and Andhra Pradesh; and one each in Bihar, Delhi, Karnataka, Punjab and Jammu and Kashmir.
India is the fourth worst-hit nation by the pandemic after the United States, Brazil and Russia.
Maharashtra has reported the highest number of COVID-19 cases with 74, including three foreigners, followed by Kerala at 52 including seven foreign nationals.
Prime Minister Narendra Modi on Wednesday asked states to make full use of the expanded COVID-19 testing capacity and saving lives a top priority as India recorded the highest ever spike of 2,003 coronavirus deaths after Maharashtra and Delhi added earlier fatalities not attributed to the disease.
The BJP's manifesto speaks about the Prime Minister's vision of making 'Atmanirbhar Bihar'.
The institute expects to complete both, phase-2 and 3 trials in India by the end of this year.
The number of active COVID-19 cases stood at 13,295 while 2,301 people have been cured and discharged.
The procurement and distribution will be centralised though the government is yet to take a call on the initial number of doses that will be procured.
Some of India's biggest employers are testing for antibodies to either comply with regulatory norms or gauge the effectiveness of precautionary measures.
E-cigarettes pose a huge health risk to users, who more often than not are adolescents and young adults
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances